Related Experiment Video
Updated: Jun 15, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Pediatric antifungal therapy. Part II: neonatal infections
U Allen1, S Richardson, W McGuire
1Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. upton.allen@sickkids.ca
Abstract:
The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antifungal Agents
Cryptococcal Meningitis
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
